Clinical Trial Update: A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Creon (pancrelipase) for pancreatic exocrine insufficiency in subjects with type 2 diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency
• Type 2 Diabetes Mellitus

Drugs mentioned

• Creon (pancrelipase)

Snippet

Sponsor: Abbott | Conditions: Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2 | Phase 4 | Status: WITHDRAWN